NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: GLAXO · data 2026-10-30
GlaxoSmithKline Pharmaceuticals Limited
In plain words
Price: 20.1% below its 52-week high of ₹3,120.7.
Delivery: 57.5% of traded shares were kept for delivery over the last 10 sessions, against 52.5% over the last 60.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹3,955 cr |
| Net profit (last 12 months) | ₹1,068 cr |
| Sales growth, 3 years (yearly) | 5.5% |
| Profit growth, 3 years (yearly) | 19.3% |
Smart-money activity
16/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 4/30: Delivery 51.1% over the last 20 sessions vs 47.6% in the 40 before (1.07x); shares delivered per day 0.38x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 7/15: 9 schemes hold it, about ₹803 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Dividend
- 29 May 26Dividend Dividend ₹57 (ex-date) -4.0% next session
- 30 May 25Dividend Dividend ₹42 (ex-date) +0.2% next session
- 7 Nov 24Dividend Dividend ₹12 (ex-date) -2.6% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Common questions
Is GlaxoSmithKline Pharmaceuticals Limited debt-free?
Its latest reported debt-to-equity ratio is 0.01, which is very low.
What is GlaxoSmithKline Pharmaceuticals Limited's P/E ratio?
About 39.6, based on the last 12 months' earnings and a price of ₹2,494.3 (data 2026-10-30).
What is the 52-week high and low of GlaxoSmithKline Pharmaceuticals Limited?
The 52-week high is ₹3,120.7 and the 52-week low is ₹2,088.1.
Mutual funds holding GlaxoSmithKline Pharmaceuticals Limited
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 9 schemes holding about ₹803 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| SBI Midcap Fund | SBI Mutual Fund | 1.40% | ₹326 cr |
| NIPPON INDIA PHARMA FUND | Nippon India Mutual Fund | 3.11% | ₹285 cr |
| SBI Dividend Yield Fund | SBI Mutual Fund | 1.55% | ₹125 cr |
| ADITYA BIRLA SUN LIFE MNC FUND | Aditya Birla Sun Life Mutual Fund | 1.57% | ₹48 cr |
| SBI Quant Fund | SBI Mutual Fund | 0.39% | ₹10 cr |
| ADITYA BIRLA SUN LIFE PHARMA & HEALTHCARE FUND | Aditya Birla Sun Life Mutual Fund | 0.83% | ₹9 cr |
| ADITYA BIRLA SUN LIFE BSE 500 QUALITY 50 INDEX FUND | Aditya Birla Sun Life Mutual Fund | 0.80% | ₹1 cr |
| Mirae Asset Nifty 500 Healthcare ETF | Mirae Asset Mutual Fund | 0.85% | ₹0 cr |
| Mirae Asset BSE 500 Dividend Leaders 50 ETF | Mirae Asset Mutual Fund | 0.51% | ₹0 cr |
Similar companies
Abbott India Limited (ABBOTINDIA) · Gland Pharma Ltd. (GLAND) · IPCA Laboratories Limited (IPCALAB) · Ajanta Pharma Limited (AJANTPHARM) · Emcure Pharmaceuticals Limited (EMCURE)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open GLAXO in NSE Scanner →